STAT

Gottlieb blasts high insulin prices, touts far-off new rules he says will spur competition in that market

FDA's Scott Gottlieb says the price is of insulin is “not acceptable” — and his agency put out new guidance Tuesday he says will eventually help spur competition in that…
FDA Commissioner Scott Gottlieb

WASHINGTON — FDA Commissioner Scott Gottlieb blasted insulin makers Tuesday for what he called unacceptably high prices for a decades-old drug. And he rolled out a slate of new guidances for the industry he says will spur competition in the insulin market and bring down the drug’s cost when they take effect in

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanders’ Pharma Pressure Campaign, AstraZeneca’s New ADC Factory, And More
Sen. Bernie Sanders is testing the limits of the powers of a Senate chairman with little hope of advancing his drug-pricing agenda legislatively.
STAT1 min read
Opinion: HHS’s Proposed Rule Pays Lip Service To Addressing The Climate Crisis, The Greatest Threat To Human Health
HHS's proposal for addressing the climate crisis serves as an example of what historian and philosopher Hannah Arendt defined as the "banality of evil."
STAT1 min read
STAT+: Pharmalittle: We’re Watching BIO Layoffs, AstraZeneca Plans To Double Revenue, And More
The Biotechnology Innovation Organization on Monday announced 30 layoffs that are part of a restructuring.

Related Books & Audiobooks